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ABSTRACT
Purpose In earlier studies, the corn protein zein is found to be
suitable as a sustained release agent, yet the range of drugs for
which zein has been studied remains small. Here, zein is used
as a sole excipient for drugs differing in hydrophobicity and
isoelectric point: indomethacin, paracetamol and ranitidine.
Methods Caplets were prepared by hot-melt extrusion (HME)
and injection moulding (IM). Each of the three model drugs
were tested on two drug loadings in various dissolution media.
The physical state of the drug, microstructure and hydration
behaviour were investigated to build up understanding for the
release behaviour from a zein based matrix for drug delivery.
Results Drug crystallinity of the caplets increases with drug
hydrophobicity. For ranitidine and indomethacin, swelling
rates, swelling capacity and release rates were pH dependent
as a consequence of the presence of charged groups on the
drug molecules. Both hydration rates and release rates could
be approached by existing models.
Conclusion The drug state and pH dependant electrostatic
interactions are hypothesised to influence release kinetics.
Both factors can potentially be used to influence release
kinetics release, thereby broadening the horizon for zein as a
tuneable release agent.
KEY WORDS controlled release . diffusion mechanism .
dissolution kineticsmodelling . extrusion-injectionmoulding .Zein
ABBREVIATIONS
ATR-FTIR Attenuated Total Reflection Fourier
Transform Infrared Spectroscopy
DSC Differential Scanning Calorimetry
HME Hot-melt extrusion
HME-IM Hot-melt extrusion-injection moulding
IM Injection moulding
PXRD Powder X-ray diffraction
SEM Scanning electron microscopy
Tg Glass transition temperature
XRT X-ray tomography
INTRODUCTION
In the field of sustained and controlled release, biopolymers
are increasing in popularity as compared to synthetic poly-
mers, since they have the advantages of being biocompatible,
environmentally sustainable and often inexpensive. An exam-
ple is the maize corn protein zein, which has proven to be
quite promising for sustained release applications. Indeed, it
has been studied for controlled release in formats such as
microcapsules (1,2), fibers (3,4), films (5) and monolithic de-
vices (6,7). Sustained drug release is often required tomaintain
a steady drug plasma concentration for a longer period of
time, or to target the drug release to the lower intestinal region
in order to maximise absorption. Ideal polymers for sustained
release are biocompatible, nontoxic, physically, chemically
and microbiologically stable and most important of all, pro-
viding a slow but tuneable release (8).
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Zein is a major storage protein in maize corn and is a main
by-product from bioethanol production by both wet and dry
milling (9). It consists of α-, β-, γ- and δ-zein, which are pro-
teins with different molecular weights and modes of extraction
(10,11). The α-zein is the predominant protein whose struc-
ture is a triple superhelix (12). The yellow colour of the pow-
der is due to the lutein, localised in the non-polar interior of
this helix. Possibly due to this structure, zein is relatively heat
and pH stable (13), water insoluble, but soluble in aqueous
ethanol (14). The protein has hydrophobic and hydrophilic
domains, but due to its insolubility in water, it is frequently
considered to be a hydrophobic protein (15). However, the
hydrated protein is found to absorb more water upon heating
indicating a hydrophilic nature (14). A similar conclusion is
based on the calculated hydration energy of the protein on the
basis of calculated hydration energies (14) The combination of
these characteristics and its biocompatibility (15) and anti-
oxidative activity (16) make it a good candidate as sustained
release matrix material.
The use of zein micro- and nanoparticles as drug delivery
devices (produced by the use of an anti-solvent precipitation
process) has been reported by a number of groups (1,2,17). In
these studies, in vitro sustained drug release profiles were re-
ported. However, in the presence of pepsin, quick degradation
of zein occurs (1), leading to equally quick disintegration and
high drug release rates. The use of electrospinning and
electro-spraying to create zein nanofibers and nanoparticles
have also been reported (3,4,15). For these systems there are
problems in maintaining the stability of the fiber- and particle
morphologies that at this stage still need to be solved by
crosslinking the zein molecules (15). An interesting observa-
tion made in these papers is that electrostatic interactions,
between the drug and the zein matrix, contribute significantly
to the compatibility between the drug and zein (15,18).
The preferred and most widely used mode of drug delivery
is still oral delivery in the form of tablets. Some work has
already been performed on macroscopic zein based devices
for oral administration (6,7,19). The advantage of using zein
for macro scale devices is that the effect of degradation of the
zein network by pepsin, will be much less of a problem in
engineering sustained release since at the macroscale, hydra-
tion of zein by itself already takes hours (6). Previously zein has
been investigated as a tableting excipient for the sustained
release of theophilline. It was found that compression of the
zein led to high elastic recovery after pressing and resulted in
unacceptable grooving inside of the tablets (7). To bypass such
problems, we have recently investigated the use of zein as a
hot-melt extrusion-injection moulded (HME-IM) caplet ex-
cipient (6). After HME-IM, zein caplets loaded with a model
drug (paracetamol) showed a close to diffusion-controlled
sustained release: the release could be precisely tuned via the
device dimensions, and was found to be nearly independent of
drug loading.
Paracetamol is a moderately hydrophilic, unchargedmodel
drug. In order to be useful as a general excipient it is crucial to
understand how factors, such as, drug hydrophobicity and the
presence or absence of charged groups on the drugs, affect the
interaction with the zein matrix and hence, the release profile.
Therefore, we study the drug release behaviour of HME-IM
zein caplets for a range of model drugs. In addition to para-
cetamol, we also investigate the highly hydrophilic drug ranit-
idine (which is positively charged at low pH) and the hydro-
phobic drug indomethacin (which is negatively charged at
high pH). Zein has an isoelectric point (pI) around neutral
pH values. Therefore we expect to find differences in release
rates as a function of pH, caused by changes in the electrostatic
interactions of the drugs with the zein matrix. This is the first
report on the influence of drug hydrophobicity and pH on the
mechanism of drug release from macroscopic zein matrices.
First we use DSC and PXRD to characterise the caplets in
terms of drug crystallinity. X-ray tomography (XRT) is used
together with scanning electron microscopy (SEM) to investi-
gate the microstructures of the caplets before and during the
drug release process. Finally, we study both the swelling- and
drug release kinetics of the caplets, for a range of pH values.
MATERIALS AND METHODS
Materials
Purified zein protein flakes were obtained fromAcros organics
(Geel, Belgium). In order to decrease particle size to ensure
good mixing with the different crystalline drugs, it was ground
using a kitchen blender. The grinding process consisted of
cycles of 15 s grinding followed by a 20s of cooling, to mini-
mise thermal damage to the protein as a result of frictional
forces. Grounded zein powder particle size was roughly be-
tween 50–250 μm as estimated from microscopy images. The
drugs used, i.e., paracetamol, indomethacin and ranitidine,
were all obtained from Sigma Aldrich (Gillingham, UK).
Extrusion and Injection Moulding
Distilled water (10–12%of weight mixture) was mixed with the
ground zein powder in a glass mortar and pestle, to lower the
glass transition temperature (Tg) of zein, so hot-melt extrusion
could be performed at a relatively low temperature. Drug was
added to the zein-water mixture to obtain the mixes for for-
mulations with drug loading of 4.4 and 22.2% (w/w). The
ternary mixes (zein-water-model drug) were ground again pri-
or to extrusion. A batch of 5–10 g was processed using a
HAAKE™ Minilab extruder (Thermo Fisher, Karlsruhe,
Germany) with a co-rotating twin screw. Extrusion tempera-
ture was 80°C, the screw speed was 100 rpm and no die was
used. Extrudates were collected in a pre-heated injection
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moulding cylinder (80°C) which was attached to the extruder.
Also the IM process was performed at 80°C, under high pres-
sure of 300–350 bar, where the still flexible extrudate was
pressed into a caplet mould using a HAAKE™ MiniJet Pro
Piston InjectionMoulding System (Thermo Fisher, Karlsruhe,
Germany). After the IM sequence, the mould was placed on
aluminium foil positioned on dry ice for a rapid cooling. The
caplet (5.9x4.4x19.7 mm) was ejected out of the mould and
stored in a sealed container at ambient conditions.
Differential Scanning Calorimetry (DSC)
DSC experiments were conducted using a Q2000 MTDSC
(TA Instruments, Newcastle, DE, U.S.). A full range calibra-
tion was performed prior to sample testing. For the DSC
samples, a caplet slice was cut and milled into smaller particles
using mortar and pestle. Prior to the DSC measurements, all
samples were dried in a desiccator above phosphorus pentox-
ide, for 4 days at room temperature, to minimize the effect of
water evaporation during a DSC run. A standard heat-cool-
heat sequence was applied for all samples, with 10.00°C/min
heating rate and 5.00°C/min cooling rate. In the DSC cell a
nitrogen purge at a flow rate of 50mL/min was used. Analysis
was performed using TA Universal Analysis software. To
measure the amount of crystalline drug present, melting en-
thalpies were compared with the melting enthalpy of pure
crystalline drug. Melting enthalpies for pure indomethacin,
paracetamol and ranitidine were experimentally measured
at respectively 98.0±1.1 J/g, 181.0±0.7 and 130.0±2.1 J/
g. For ranitidine melting is quickly followed by degradation.
Therefore the apparent melting enthalpy may be heating rate
dependent but, provided the rate is kept constant in all the
experiments amounts of crystalline material may be estimat-
ed. The DSC measurement is only semi-quantitative as there
may be dissolution of the drug during the heating process and
the calculation neglects any contribution from the entropy of
dissolution of the drug after melting. However as the mixture
is unstirred during the heating process dissolution before melt-
ing is likely to be very small. Similar a significant error due to
dissolution after melting would require a rapid diffusion of the
drug away from its location and into the matrix which is not
likely. Apparent melting enthalpy may be heating rate depen-
dent but, provided the rate is kept constant in all the experi-
ments a semi-quantitative estimate of crystalline material may
be made.
X-ray Tomography (XRT)
XRT images were taken using a Phoenix v[tome]x m
(General Electric, Wunstorf, Germany). This technique allows
non-invasive measurement of the 3D structure of objects at
spatial resolution below 1 μm. A 3D image of a fixed particle
can be reconstructed from a large series of two-dimensional
radiographic images taken around a single axis of rotation
(20). The following settings were applied: voxel size: 4 μm,
amount of images: 2000, Voltage 100 kV, Current 110 μA
and timing 500: ms
Powder X-Ray Diffraction (PXRD)
PXRD measurements were performed on caplets and pure
powders using a Thermo Scientific™ ARL™ X’TRA
Powder Diffractometer (Ecublens, Switzerland) fitted with a
Cu (copper) x-ray tube. The following operating conditions
were used: current, 40mA; voltage, 45 kV; step size, 0.01° and
acquisition time of 1.0 s/step.
Scanning Electron Microscopy (SEM)
Caplet pieces, cut using a razor blade, were attached to sam-
ple holders with carbon adhesive tabs (EMS, Washington,
USA) and sputter coated with 10 nm Iridium (SCD 500,
Leica, Vienna, Austria). Hereafter they were analyzed with
secondary electron detection at 2 KV and 6.3 pA with a high
resolution scanning electron microscope (Magellan 400, FEI,
Eindhoven, the Netherlands).
Dissolution and Hydration Media
Media with 4 different pH’s were prepared. The pH 1 solu-
tion was a 0.1 M HCl solution. The pH 5.5 medium was a
sodium acetate-acetic acid buffer. Both the pH 6.8 and pH 7.8
media were phosphate buffers prepared from potassium
dihydrogen phosphate and sodium hydroxide.
Hydration Studies
Hydration was measured gravimetrically. Caplets (diameter
5.9 mm) were carefully cut into slices (thicknesses was 2.20±
0.03 mm) by the use of a razor blade. Slice thicknesses and
weight were measured respectively using an electronic calliper
and a microbalance. Caplets were immersed in a medium
solution at 37°C with 50 rpm paddle rotation speed. At reg-
ular time intervals, the samples were removed from the disso-
lution bath. Excess water was gently removed using a piece of
paper towel before weighing the samples. Subsequently the
samples were immediately returned to the solution. The
weight change of the samples was monitored over a period
up to 70 h. The water uptakeM (gwater/gzein) was determined in
2 steps. First the initial sample weight minus the weight of the
released drug (based on the Peppas fits on the data obtained
from the release experiments (see Fig. 5 and Table II), was
subtracted from the measured wet weight of the sample.
Then, the obtained increased weight was divided by the dry
weight of the zein in the sample. All hydration experiments
were performed in triplicate.
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Dissolution Studies
Dissolution experiments were performed using the paddle
method with 900 ml of dissolution media at 37.0±0.5°C
and a 50 rpm rotation speed of the paddles. Caplets were
carefully cut into slices, which were measured and weight as
in the hydration experiments. Release kinetics was measured
at regular time intervals. 10 ml samples were taken and mea-
sured using a UV/vis spectrophotometer (S-22 Boeco,
Boeckel and Co., Hamburg, Germany) at 243 and 314 nm
corresponding to the λmax of respectively paracetamol and
ranitidine. Because indomethacin has a low saturation con-
centration in water, a biphasic dissolution method needed to
be applied on indomethacin loaded caplets, to keep the chem-
ical potential difference between the sample and the dissolu-
tion medium constant. Caplets were immersed in 600 ml me-
dium, while on top a 300 ml octanol phase was present.
Release was measured in the octanol phase by UV/vis at
319 nm, corresponding to a λmax of indomethacin. In dissolu-
tion media where pH is above pKa (which is around 4.2),
indomethacin is negatively charged, which could decrease up-
take in octanol and theoretically disrupt the test. However
when testing the release of drug crystals at pH of 6.8, it was
found to be very fast compared to other pH’s as can be seen in
Fig. 9c. Therefore we have no reason to believe the charge of
the drug will be disruptive for the test.
RESULTS AND DISCUSSION
Drug-Zein Compatibility
To assess the compatibility between zein and the model drugs,
it is not possible to use theoretical Flory-Huggins based drug-
excipient miscibility prediction methods, such as ground con-
tribution and solubility parameters methods (21), as zein pro-
tein has a complex structure. A first indicator for the drug-
matrix compatibility is the influence of drug loading on the
processability during hot-melt extrusion-injection moulding
(HME-IM), as reflected by the extrusion torque. A higher
torque indicates poorer zein-drug miscibility or poorer
plasticisation of the zein matrix by the drug.
Our results for the extrusion torque for the model drugs (at
two different drug loading) are shown in Table I. We the
found that loading the zein matrices with the hydrophilic drug
ranitidine reduces the extrusion torque. On the other hand,
loading the matrix with the hydrophobic drug indomethacin
increases the torque. For paracetamol we find an intermediate
result, with little or no changes in the torque compared to the
unloaded zein. As we will discuss more extensively in a later
section, the changes in torque reflect the zein-drug miscibility
at the temperatures at which extrusion occurs. We verified
that small variation in moisture content (0.12–0.14 (w/w))
did not influence the torque values during extrusion (data
not shown).
The degree of crystallinity of the drugs in the caplets was
determined using both PXRD and DSC. PXRD results are
shown in Fig. 1. For the most hydrophobic drug, indometha-
cin, we find some degree of crystallinity of the drugs in the
caplets for both drug loadings (4.4% and 22.2%). For the
paracetamol, only the caplets with a drug loading of 22.2%
have some degree of crystallinity, in agreement with our pre-
viously published work (6). For the most hydrophilic drug,
ranitidine, we find no indications of crystalline drug present
in any of the caplets.
The corresponding DSC data is shown in Fig. 2 and con-
firms the PXRD results. In addition, for the case of indometh-
acin, we use the DSC data to quantify the fraction of drug in a
crystalline state, from the melting enthalpy of the crystalline
drug melting peaks. This estimate is only semi-quantitative, as
discussed above. We find that at 4.4% loading, the estimated
degree of crystallinity is 0.3%. This increases to 13% at the
higher drug loading of 22.2%.
Overall, our PXRD and DSC data show that the degree of
crystallinity increases with hydrophobicity of the drug and also
with drug loading. The degree of crystallinity is in line with the
differences we observe in the HME processability of the three
model drugs. The HME-IM temperature was set at 80°C
which is still significantly below (70–90°C) the melting points
of the drugs. Crystals which remained undissolved during
HME could act as a filler (22) and this can explain the increase
in extrusion torque for indomethacin. For the case of raniti-
dine, for which extrusion torques are lowest of all used mixes,
we believe that the drug acts as a plasticizer of the zein. Note
that the loss of crystallinity during extrusion is significant for all
of the drugs we tested. We believe this cannot be caused by
dissolution of the drug in the small amount of water used
during the pre-mixing stage of the sample preparation, since
the saturation concentrations of indomethacin, paracetamol
and ranitidine around pH=6.5 are respectively 0.33 g/L (23),
17.4 g/L (24) and 660 g/L (25). Given the water contents of
the mixes (which are below 0.14 w/w), the theoretical maxi-
mal dissolution of drugs in water at 20°C would be, respec-
tively 3.9°10−3, 0.2 and 7%. The increased solubility at the
Table I Average Extrusion Torque for Each Drug Loading. Extrusion
Torque Increase with Drug Hydrophobicity. Paracetamol Extrusion Torque is
Most Similar to that of Unloaded Zein
Average extrusion torque (Ncm)
Drug loading Zein Indomethacin Paracetamol Ranitidine
No drug 30
4.4% drug 40 30 20
22.2% drug 45 30 20
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temperatures of extrusion (80°C) are also insufficient to ex-
plain the large decrease of the degree of crystallinity. For in-
stance, we estimate that the theoretical maximal dissolution of
paracetamol in the water present in the caplet at 80°C, can
increase to only 1.5% at most, based upon extrapolation of
published solubility curves (26).
Therefore, the most likely explanation is that the zein/
water matrix ‘solubilizes’ the drugs during extrusion. The
amount of drug that is dispersed in the matrix may be expect-
ed to correlate inversely with the drug hydrophobicity.
Nevertheless, even the hydrophobic indomethacin appears
to be solubilized to a significant extent, as reflected by the
large decrease of the degree of crystallinity upon incorporat-
ing the indomethacin in the zein matrix viaHME. Therefore,
we conclude that zein, processed using HME, is efficient at
bringing a range of drugs into a non-crystalline state, which
may be beneficial for drug delivery applications. This will be
especially important when the dissolution of the drug crystals
is slower than desired.
Microstructures of the Drug-Loaded Caplets
We first investigate the structure of the drug-loaded caplets on
the micrometer length scale, using XRT. Figure 3 shows
Fig. 1 PXRD results of caplets
containing different drug loadings
(%), indicating crystallinity of the
drug in the different caplets. Drugs
loadings are 22.2%( ) and
4.4%( ) are displayed together
with pure drug ( ). Drugs used are
(a) Indomethacin, (b) paracetamol
and (c) ranitidine. Results show
increase in crystallinity with drug
hydrophobicity in the HME-IM
processed caplets.
Fig. 2 DSC thermograms of the
zein/drug caplets containing
different drug loadings: 22.2% ( )
and 4.4%( ). Heat flow (W/g) is
plotted vs Temperature T (°C).
Drugs are (a) Indomethacin, (b)
paracetamol and (c) ranitidine. A
reduced curve ( ) of the pure drug
is added as comparison. Melting
enthalpy is displayed for caplets if
melting peak was present.
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XRT images (with a resolution of around 5 μm) of an
unloaded zein caplet and of 3 zein caplets loaded with
22.2% of each of the three model drugs. For the caplets con-
taining indomethacin and paracetamol, we observed domains
with a significantly higher density than the background (indi-
cated in red in Fig. 3). For indomethacin the volume percent-
age of these domains is 9.1%, while for paracetamol the
volume percentage of these domains was only 2.1%. In both
samples the domains are largely homogeneously distributed in
the bulk of the caplet. For indomethacin caplets, it appears
that there is a higher concentration of such domains close to
the surface of the caplets. We found that during processing
some air was included in the caplets, leading to some degree of
porosity. Differences in porosity could influence the rate of
Fig. 4 SEM images of drug-loaded zein caplet cross sections. (a) unloaded zein, (b) 22.2% ranitidine, (c) 22.2% paracetamol and (d) 22.2% indomethacin. The
insert of each picture shows a zoom of the area displayed by the smaller red box.
Fig. 3 XRT images of caplets,
showing presence and distribution
of denser (drug) domain (in red)
together with volume for air
pockets. (a) unloaded zein, (b)
22.2% ranitidine, (c) 22.2
paracetamol and (b) 22.2%
indomethacin. Volume of air
pockets (%) is displayed for each
caplet.
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hydration, but also the release rate as hypothesised in an ear-
lier study on zein membranes (5). From the estimated vol-
ume percentage of pores (see Fig. 3), the ranitidine and
indomethacin loaded samples are found to have a
higher volume percentage of pores than the paraceta-
mol loaded and unloaded zein caplets. For all measured
systems, the overall volume fraction of the pores is in
the order of a few percent.
Next we used SEM to investigate the same microstructures
at an even higher resolution. Figure 4 shows representative
SEM images for an unloaded zein caplet and for caplets load-
ed with 22.2% of each of the three model drugs. The images
for the paracetamol loaded caplets are similar to those for the
unloaded zein caplets. According to the SEM images, caplets
with ranitidine appear to have a significantly more smooth
surface compared to the other caplets. Finally, for indometh-
acin loaded caplets, the SEM images clearly show the pres-
ence of distinct particle-like structures, that could be the dis-
persed indomethacin crystals. The SEM images also demon-
strate the presence of pores at smaller length scales than those
probed by XRT. Hence the actual porosity of the caplets may
be somewhat higher than the values estimated on the basis of
XRT (see Fig. 3).
An important observation is that the volume percentage of
the domains with a higher electron density in XRT (shown in
red in Fig. 3) is similar to the degree of crystallinity as estimat-
ed on the basis of the DSC results. This strongly suggests that
the dense domains in the XRT images can be identified as the
drug crystals dispersed in a zein-drug matrix. The SEM im-
ages also confirm that only in the indomethacin caplets a
significant fraction of crystals is present. It was also observed
that many of these crystals are located in the pores of the
caplet caused by the incorporation of a small fraction of air
during the processing, as shown clearly in supplementary ma-
terials Figure S1.
The porosity due to the air incorporated in the caplets,
was found to be higher for indomethacin and ranitidine
than for the paracetamol and unloaded caplets. This may
or may not be related to the fact that both indomethacin
and ranitidine strongly influenced the extrusion torque.
Even though the actual volume fraction of air that causes
porosity is not high, the differences in porosity that we
observe should be born in mind, in view of the large effect
that such pores were suggested to have on release hydra-
tion and release properties .
Hydration and Swelling Kinetics
The hydration and swelling behaviour is expected to influence
the release behaviour of matrix-based delivery systems. Water
uptake of all samples was measured in two different dissolution
media, HCl solution (pH 1) and phosphate buffer (pH 6.8) (see
Fig. 5), which were also used in the dissolution experiments.
The data was fitted to the Peleg (27) equation, which is widely
used as empirical equation to fit water uptake of matrices:
M tð Þ−M 0 ¼ tK 1 þ K 2t ð1Þ
Fig. 5 The water uptakeM (gwater/gzein) as a function of time t (h) for the different
caplets used. Drug loadings at 4.4% (▲,△), 22.2% (■,□) and no (♦,◇) drug
loading in pH 1 (▲,■,◆) and pH 6.8 (△,□,◇). The drugs tested are (a) indometh-
acin, (b) paracetamol and (c) ranitidine. In all graphs, the water uptake curve of
non-loaded zein caplets is added as comparison. The lines are fits using the Peleg
model, Eq 1, to caplets in pH 1 (continious line) and pH 6.8 (dashed line) medium.
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where M(t) is the moisture content (gwater/gzein) at time t (min),
M0 is the initial moisture content, K1 is the Peleg rate constant
(min∙(gwater/gzein)−1) and K2 is the Peleg capacity constant (gwater/
gzein)
−1. The values of the fitting parameters 1/K1 and 1/K2 for
the different caplets are shown in Table II.
For all caplets, both the hydration rates (1/K1) and the
swelling capacity values (1/K2) are much higher at pH 1 as
compared to the values at pH 6.8. Hydration rates (1/K1) of
paracetamol caplets are comparable to those of unloaded zein
caplets, while hydration rates (1/K1) of indomethacin caplets
are slightly lower and decrease with drug loading. For 22.2%
loaded ranitidine caplets we find hydration rates that are
much higher than those of unloaded caplets (~16.5 times
higher at pH 1 and about 11 times higher at pH 6.8). As for
the dependence of the swelling capacity (1/K2) on the drug
loading ratio, we find qualitatively different behaviour at pH 1
and pH 6.8. At pH 1 an increased drug loading has an in-
creasing (for paracetamol and ranitidine) or decreasing (for
indomethacin) effect on the swelling capacity. In contrast, at
pH 6.8 caplets loaded with indomethacin and paracetamol
show very similar swelling capacity as compared to values
for the unloaded zein caplets. This is not the case for ranitidine
caplets since they show an increase of 1/K2 at pH 6.8 com-
pared to unloaded zein caplets.
The influence of pH on both hydration rate and swelling
capacity can be related to the charge of the zein protein. The
Fig. 6 XRT pictures of caplets
hydrated for 96 h at pH 1 and
subsequently vitrified and freeze
dried. The zein caplets were loaded
as follows: (a): no loading, (b):
22.2% rantidine, (c):22.2%
paracetamol, (d): 22.2%
indomethacin. Radial cracks are
most likely caused by the vitrification
process.
Table II Fitting Parameters of the Caplet Hydration Data of A) Unloaded Caplets and b) Caplets with Different Drug and Drug Loadings in Different Media. For
Fitting the Peleg Equation (Eq 1) was Used, Where 1/K1 Displays Initial Hydration Rate and 1/K2 is a Measure of Swelling Capacity
A
Zein
102⋅1=K 1
g=g zein
min
1=K 2 g=g zein
R2
pH=1 0.52 1.52 0.996
pH=6.8 0.21 0.75 0.997
B
Indomethacin Paracetamol Ranitine
Drug loading,
pH 102⋅1=K 1
g=g zein
min
1=K 2 g=g zein
R2
102⋅1=K 1
g=g zein
min
1=K 2 g=g zein
R2
102⋅1=K 1
g=g zein
min
1=K 2 g=g zein
R2
4.4%, pH=1 0.41 1.64 0.998 0.52 1.56 0.998 0.71 1.74 0.995
4.4%, pH=6.8 0.15 0.85 0.996 0.25 0.79 0.994 0.64 1.13 0.994
22.2%, pH=1 0.32 1.32 0.996 0.50 1.89 0.990 8.33 1.86 0.982
22.2%, pH=6.8 0.18 0.79 0.997 0.21 0.69 0.990 2.33 1.10 0.956
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zein predominantly consists of α-zein, which has an isoelectric
point of pI 6.8, hence at pH 1 zein is positively charged and at
pH 6.8 it will be uncharged. As a result, at pH 1 the proteins
will have more counter ions present which increases the os-
motic pressure in the caplet and cause an increase in swelling
(28). Another possible contribution to faster swelling at pH 1
may be the de-amidation of glutamine and asparagine amino
acids of the zein (29), which may also lead to a more open
network. At identical drug loadings, both hydration rate and
swelling capacity decrease with drug hydrophobicity, since the
addition of the hydrophobic drugs to the zein matrix simply
makes the combined system more hydrophobic. Probably,
once the hydration takes place, the drug dissolution leads to
an decrease of the chemical potential of the water in the ma-
trix resulting in the uptake of water by the matrix.
Next, the dynamic changes in the microstructure of the
caplets caused by hydration and swelling were studied in more
detail using XRT. After 96 h of hydration, the caplets were
rapidly vitrified in liquid nitrogen and subsequently freeze-
dried. XRT images of caplets that were hydrated at pH 1
Fig. 8 Light microscopy image of
(untreated) hydrated caplet slices
compared with XRTof vitrified and
freeze dried hydrated caplet (insert).
(a) 22.2% paracetamol pH=6.8
(b) 22.2% ranitidine pH=6.8 (c)
22.2% indomethacin pH=6.8 (d)
zein pH=1
Fig. 7 XRT pictures of caplets
hydrated for 96 h at pH 6.8 and
subsequently vitrified and freeze
dried. The zein caplets were loaded
as follows: (a): no loading, (b):
22.2% rantidine, (b):22.2%
paracetamol, (d): 22.2%
indomethacin. Radial cracks are
most likely caused by the vitrification
process.
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and pH 6.8 are shown in Figs. 6 and 7. The similarity of the
XRT images of the freeze-dried caplets and the light micros-
copy images of wet hydrated caplets (Fig. 8), confirmed that
the freeze-drying process did not affect most of the interior
microstructures of the caplets, with the exception of the for-
mation of the radial cracks.
In both Figs. 6 and 7, it can be observed that the zein and
paracetamol-loaded caplets, show pronounced concentric cir-
cular cracks after hydration, similar to tree rings. For the ra-
nitidine and indomethacin-loaded caplets, the cracks are
much less pronounced. In the ranitidine sample the concentric
circular cracks are still visible, while in the indomethacin sam-
ple they are only visible at the outer region close to the surface
of the caplet. Previously, it was suggested that the cracks are a
result of stresses on the network due to hydration (30). The
correlation that we find between on the one hand hydration
rates and capacities (Table II) and on the other hand the
occurrence of the circular cracks (Figs. 6 and 7) is therefore
expected. The circularity of the cracks may be explained if we
assume that hydration is controlled by case II diffusion (6).
Since for case II diffusion there is a sharp boundary between
the hydrated and unhydrated parts of the caplet, rupture is
expected to take place at this boundary, that migrates inwards
driven by the hydration process. For the ranitidine caplets the
concentric cracks are much finer. This could be a consequence
of the higher fraction of air and associated porosity of the
ranitidine caplets. The pores might relieve some of the stress
due to the passing hydration front, leading to a finer crack
structure.
Drug Release
Release profiles for paracetamol and ranitidine loaded caplets
were measured by the conventional dissolution method, while
for the caplets containing the poorly soluble indomethacin,
the biphasic dissolution method was used (31). Here, an
octanol phase was added to maintain sink conditions in the
aqueous phase throughout the dissolution test. The indometh-
acin that is dissolved in the aqueous phase, is expected to be
efficiently extracted by the octanol. For each drug an addi-
tional medium (with pH 7.8 or pH 5.5) was tested to further
investigate the influence of pH on release kinetics. Results are
shown in Fig. 9 and also shown are fits of the release profiles to
the Peppas equation (32):
Q tð Þ
Q ∞
¼ ktn ð2Þ
Here Q is the mass of drug released at time t (minutes) and
Q∞ is the mass of drug release as time approaches infinity. The
parameter k depends on the characteristics of the excipient-
drug network, while n is an exponent indicative for the trans-
port mechanism. For the cylindrical geometry of the caplets
with a slice thickness-to-diameter ratio of 2.7, two limited
mechanisms can be identified. When the release kinetics is
controlled by pure Fickian diffusion (driven by a chemical
potential gradient (33)), the expected value is n=0.45. On
other hand, when release is controlled by Case II diffusion
(commonly associated with a glass-to-gel transition of the ma-
trix, for which the matrix hydration step is controlling the
release rate (33)), the expected value is n~0.9. The same value
for n may also be found for very poorly soluble drugs, when
release is limited by the dissolution rate of the drug. Values for
the parameters k and n determined by fitting the Peppas mod-
el to the experimentally observed release kinetics for the three
Fig. 9 Release profiles for slices of caplets at pH 1 (◇, ◆), pH 5.5 (○,●),
pH 6.8 (■, □) and pH 7.8 (▲, △). The caplets were loaded with (a) ranitidine,
(b) paracetamol and (c) indomethacin, with a 4.4% loading (△,□,◇,○) and a
22.2% loading (▲,■,◆,●). The lines show data fits using the Peppas model,
given by Eq. 2., to caplets with a 4.4% drug loading (dashed line) and a 22.2%
drug loading (continuois line). In (c), release from pure indomathcin crystals
shown at pH 1 (+) and pH 6.8 (−) (see insert).
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model drugs (up to a released fraction of 0.6) are given in
Table III. For ranitidine and paracetamol caplets, values for
the half-life (indicative for the typical release time) are also
given in Table III.
A first observation is that for most paracetamol and ranit-
idine caplets, the exponent n is between 0.45 and 0.65, while
for indomethacin caplets, the value of n is on average 15%
higher. For paracetamol loaded caplets the release kinetics is
almost independent of drug loading and release medium, in
line with earlier results (6). For ranitidine, release rates drop
significantly at the highest pH (pH 7.8), but increase with drug
loading.With the exception of 22.2% loaded caplets at pH 6.8
and pH 7.8, the ranitidine caplets appeared to show slower
release rates compared to paracetamol caplets. Not unexpect-
edly, indomethacin caplets showed a much slower release as
compared to caplets containing paracetamol and ranitidine.
The release rate for the indomethacin caplets was highest at
pH 6.8, and lowest at more acidic pH values (lowest at pH 5.5
for 4.4% caplets and lowest at pH 1 for 22.2% caplets). Except
at pH 1, the release kinetics was found to be quite insensitive
to drug loading. The release kinetics of the paracetamol and
ranitidine are found to be close to Fickian diffusion. The
values of n that we find for indomethacin, at pH 1 indicate
that here the limiting step is the dissolution of amorphous or
crystalline drug particles. The solubility of indomethacin is
known to be strongly pH dependent (23) being less than
2.7 mg/L at pH 1. We have also tested release rates for indo-
methacin crystals ourselves and compared with the release
rates from caplets, as shown in Fig. 9. In the experiment, the
crystals were kept in dialysis tubes to prevent their migration
to the octanol phase. We confirmed that while at pH 6.8,
release rates from crystals is much faster than from the caplets.
For pH=1 it is just the other way around, suggesting that in
the latter case the caplet preparation procedure has molecu-
larly dissolved at least part of the drug into the matrix leading
to faster release than from crystals.
A key factor influencing the pH dependence of the release
kinetics is obviously the electrostatic interaction between the
drugs and the zein matrix. In Fig. 10 the pI of zein and the
pKa values of ranitidine and indomethacin are displayed to-
gether with their resulting charge at different pH values.
Paracetamol is not included, because it is uncharged in all test
media (34). If charges on the drug and the matrix have oppo-
site signs, there is an electrostatic attraction and the release
rate may be expected to become lower. Indeed, this is what is
observed for ranitidine. For this case we find a significant
Fig. 10 Schematic overview of the
charge of ranitidine, zein and
indomethacin at different pH’s. pKa
and pI values for the compounds
are also shown. Electrostatic
attractions are higher between
ranitidine and zein between pH 6.8
and pH 8.5 and higher between
indomethacin and zein between
pH 4.5 and 6.8.
Table III Parameters Describing the Kinetics of Release for the Different Caplets Containing Paracetamol, Ranitidine or Indomethacin. R2 Values of the Fits
Were Between 0.992 and 1.000. For Indomethacin Linear Fits Were Applied Giving a Slope and Intercept
Drug loading,
pH
Ranitidine Paracetamol Indomethacin
k∙102 n half-life (min) k∙102 N Half-life (min) k∙105 n Half-life (min∙10−4)
4.4% pH 1 2.16±0.45 0.47±0.04 761 1.93±0.27 0.55±0.03 358 4±0.6 0.84±0.04 7
22.2% pH 1 1.73±0.15 0.56±0.01 416 1.97±0.07 0.55±0.01 354 4±2 0.78±0.05 18
4.4% pH 5.5 – – – – – – 10±5 0.70±0.05 19
22.2% pH 5.5 – – – – – – 53±30 0.53±0.07 41
4.4% pH 6.8 0.67±0.07 0.67±0.07 600 1.98±0.65 0.51±0.06 553 41±8 0.63±0.05 7
22.2% pH 6.8 0.77±0.03 0.77±0.01 221 1.67±0.17 0.55±0.02 472 99±60 0.52±0.06 16
4.4% pH 7.8 0.96±0.10 0.53±0.02 1819 1.11±0.08 0.62±0.03 452 – – –
22.2% pH 7.8 1.21±0.35 0.61±0.07 454 1.62±0.11 0.54±0.02 594 – – –
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difference in release rates between the case of pH 6.8 (where
zein has no net charge) and pH 7.8 (where zein is has a net
positive charge), especially for 4.4% loaded caplets. Likewise,
for indomethacin one would expect the slowest release be-
tween pH 4.5 and pH 6.8 where the drug and matrix carry
opposite charge signs. Indeed, for 4.4% loaded caplet we find
that release at pH 5.5 is even slower than at pH 1.
The hydration rate and swelling capacity do not seem to
directly correlate with the release kinetics. As shown in Fig. 5,
hydration rate and swelling capacity are much higher at pH 1
than at pH 6.8. However, for paracetamol caplets, release is
only slightly faster at pH 1 than at pH 6.8. For ranitidine
release is even slower at pH 1 than at pH 6.8. The water
solubility of the drug does not seem to be the main determi-
nant of release kinetics either, since release of paracetamol
from the caplets was in most cases faster than the release of
the much more soluble ranitidine (20 times more soluble). For
the very poorly soluble indomethacin, solubility does appear
to be a limiting factor, since for this case release is much slower
as for the other drugs, and the diffusional exponent n that
relates to the mechanism of drug release is much higher.
CONCLUSION
We conclude that extrusion followed by injection moulding is
a suitable method for preparing sustained release caplets for a
range of drugs, varying in hydrophobicity. The caplet prepa-
ration procedure leads to a reduction of crystallinity for all
drugs, although the reduction is smallest for the most hydro-
phobic drug. We also find that electrostatic attractions be-
tween matrix and drug can significantly slow down release.
We show that depending on drug charge and hydrophobicity
zein can show a wider variety of release characteristics.
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